102 Results for "

Vegfa

" in MedChemExpress (MCE) Product Catalog:
Products (102)

102 Results for "Vegfa" in MCE Product Catalog:

  • Recombinant Proteins Recommended:
62
62 Publications Verification
Cat. No.: HY-P9906
CAS No.: 216974-75-3
Synonyms: Anti-Human VEGF, Humanized Antibody

Target:  

VEGFR

Research Areas:  

Cancer

Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.
loading...
    loading...
62
62 Publications Verification
Cat. No.: HY-P9906A
CAS No.: 216974-75-3

Target:  

VEGFR

Research Areas:  

Cancer

Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity .
loading...
    loading...
34
34 Cited Publications
Cat. No.: HY-B1788
CAS No.: 81-24-3
Synonyms: N-Choloyltaurine
Taurocholic acid (N-Choloyltaurine) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid has immunoregulation effect .
loading...
    loading...
34
34 Cited Publications
Cat. No.: HY-N0545
CAS No.: 145-42-6
Synonyms: Sodium taurocholate; N-Choloyltaurine sodium
Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .
loading...
    loading...
34
34 Cited Publications
Cat. No.: HY-B1131
CAS No.: 345909-26-4
Synonyms: Sodium taurocholate hydrate; N-Choloyltaurine sodium salt hydrate
Taurocholic acid (N-Choloyltaurine) sodium salt hydrate has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium salt hydrate has immunoregulation effect .
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-117661
CAS No.: 1818389-84-2
Target:  

SRPK VEGFR

Research Areas:  

Cardiovascular Disease Cancer

SPHINX31 is a potent and selective SRPK1 inhibitor, with an IC50 of 5.9 nM. SPHINX31 inhibits phosphorylation of serine/arginine-rich splicing factor 1 (SRSF1). SPHINX31 also decreases the mRNA expression of pro-angiogenic VEGF-A165a isoform. SPHINX31 can be used to research neovascular eye disease .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-10799
CAS No.: 1210945-69-9
Purity:  98.03%
Target:  

Complement System

Research Areas:  

Cancer

EG00229 is a neuropilin 1 (NRP1) receptor antagonist. EG00229 selectively inhibits VEGF-A binding to NRP1 b1 domain with an IC50 of 3 μM, but has no effect on VEGFA binding to VEGFR-1 and VEGFR-2 .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-P7312
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: VEGF-AA; rMuVEGF164; VPF
Species:  
Source:  
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-P80929
Synonyms: Vegfa; VEGF; Vascular endothelial growth factor A; VEGF-A; Vascular permeability factor; VPF

Host:  

Rabbit

Application:  

WB

Reactivity:  

Human, Mouse, Rat

loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-124593
CAS No.: 1256565-36-2
Purity:  99.89%
Synonyms: Emvododstat
PTC299 is an orally active inhibitor of VEGFA mRNA translation that selectively inhibits VEGF protein synthesis at the post-transcriptional level. PTC299 is also a potent inhibitor of dihydroorotate dehydrogenase (DHODH). PTC299 shows good oral bioavailability and lack of off-target kinase inhibition and myelosuppression. PTC299 can be useful for the research of hematologic malignancies .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-N2187
CAS No.: 43043-74-9
Deoxyshikonin increases the expression of VEGF-C and VEGF-A mRNA in HMVEC-dLy, promotes HIF-1α and HIF-1β subunit interaction and binds to specific DNA sequences targeted by HIF. Deoxyshikonin inhibited colorectal cancer (CRC) through the PI3K/Akt/mTOR pathway. Deoxyshikonin has proangiogenesis effect and antitumor activity. Deoxyshikonin is an antibacterial agent against methicillin-resistant S. aureus (MRSA) and S. pneumonia (MIC=17 μg/mL) .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P7311
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: rRtVEGF164; VEGF-AA; VPF
Species:  
Rat
Source:  
CHO
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N7043
CAS No.: 142796-21-2
Isosilybin A is a PPARγ agonist that can be isolated from silymarin. Isosilybin A activates extrinsic and intrinsic pathways of apoptosis through targeting of the Akt-NF-kB-AR axis. Isosilybin A can relieve the inflammatory response in the rosacea model via inhibiting Erk and p38 signaling pathways and M1 macrophage polarization, with its targets related to RELA and VEGFA. Isosilybin A has anti-prostate cancer (PCA) activity [1][2][3].
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P7420
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: VEGF-AA; rHuVEGF-121; VPF
Species:  
Source:  
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99675
CAS No.: 2428381-53-5
Synonyms: AK112

Target:  

PD-1/PD-L1 VEGFR

Research Areas:  

Cancer

Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P9951A
CAS No.: 347396-82-1
Synonyms: RG-6321 (anti-VEGF)

Target:  

VEGFR

Research Areas:  

Cardiovascular Disease

Ranibizumab (RG-6321) (anti-VEGF) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165) . Ranibizumab (anti-VEGF) slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P990148

Target:  

VEGFR

Research Areas:  

Cancer

Anti-Mouse VEGF-A Antibody (2G11-2A05) is a rat-derived IgG2a κ type antibody inhibitor, tragrting to mouse VEGF-A with high affinity. Anti-Mouse VEGF-A Antibody (2G11-2A05) shows good anti-tumor effect in gastric cancer xenograft models .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P9920A
CAS No.: 947687-13-0

Target:  

VEGFR

Research Areas:  

Cancer

Ramucirumab (anti-VEGFR) is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab (anti-VEGFR) is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P10284
CAS No.: 853248-13-2
S7 is an inhibitory polypeptide targeting IL-6R, which specifically binds to IL-6R and its A chain (gp80/IL-6RA) to block its signal transduction. S7 inhibits IL-6-mediated anti-apoptosis (apoptosis), angiogenesis and the expression of VEGF-A, blocks related survival signaling pathways, and enhances the sensitivity of cancer cells to chemotherapeutic drugs. S7 can be applied to the research of related diseases such as cervical cancer, multiple myeloma, Kaposi's sarcoma, prostate cancer and basal cell carcinoma .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P72775
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: VEGF-AA; Vascular endothelial growth factor A; VPF; Vegfa
Species:  
Source:  
loading...
    loading...